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Abstract
Purpose Somatostatin-based radiopeptide treatment is gener-
ally performed using the β-emitting radionuclides 90Y
or 177Lu. The present study aimed at comparing benefits and
harms of both therapeutic approaches.
Methods In a comparative cohort study, patients with advanced
neuroendocrine tumours underwent repeated cycles of [90Y-
DOTA]-TOC or [177Lu-DOTA]-TOC until progression of dis-
ease or permanent adverse events. Multivariable Cox regres-
sion and competing risks regression were employed to examine
predictors of survival and adverse events for both treatment
groups.
Results Overall, 910 patients underwent 1,804 cycles of [90Y-
DOTA]-TOC and 141 patients underwent 259 cycles of
[177Lu-DOTA]-TOC. The median survival after [177Lu-
DOTA]-TOC and after [90Y-DOTA]-TOC was comparable
(45.5 months versus 35.9 months, hazard ratio 0.91, 95 %
confidence interval 0.63–1.30, p =0.49). Subgroup anal-
yses revealed a significantly longer survival for [177Lu-
DOTA]-TOC over [90Y-DOTA]-TOC in patients with
low tumour uptake, solitary lesions and extra-hepatic
lesions. The rate of severe transient haematotoxicities
was lower after [177Lu-DOTA]-TOC treatment (1.4 vs
10.1 %, p =0.001), while the rate of severe permanent
renal toxicities was similar in both treatment groups (9.2 vs
7.8 %, p =0.32).
Conclusion The present results revealed no difference in me-
dian overall survival after [177Lu-DOTA]-TOC and [90Y-
DOTA]-TOC. Furthermore, [177Lu-DOTA]-TOC was less
haematotoxic than [90Y-DOTA]-TOC.
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Neuroendocrine tumour
Introduction
Neuroendocrine tumours are neoplasms arising from cells of
the endocrine and nervous systems [1]. For differentiated
neuroendocrine tumours, the therapeutic options include the
multi-targeted tyrosine kinase inhibitor sunitinib [2] and the
mTOR inhibitor everolimus [3]. For dedifferentiated tumours,
the options include chemotherapy with streptozotocin, 5-
fluorouracil and doxorubicin [4]. Importantly, most neuroen-
docrine tumours harbour subtypes of the somatostatin receptor
family [5], which permits treatment with the somatostatin
analogue octreotide [6, 7], imaging with radioactively labelled
somatostatin analogues [8] and somatostatin receptor targeted
radiopeptide treatment.
Somatostatin receptor targeted radiopeptide treatment
with DOTA-TOC (tetraazacyclododecane tetraacetic acid
modified Tyr3-octreotide, Fig. 1a) was developed and
brought into clinical use by our group in 1997 [9, 10].
Subsequently, it was established as an effective therapeutic
option for the treatment of advanced neuroendocrine tumours
[11]. DOTA-TOC is applied intravenously, is internalized
into the tumour cell via the somatostatin receptor and
irradiates the tumour with the β emission of the coupled
radioisotope.
The radioisotopes commonly used for radiopeptide ther-
apy are 90Y and 177Lu. 90Y is a high-energy β emitter that
can deliver high target doses. Its long emission range can
penetrate to tissues further away from the target tissue. On
the contrary, 177Lu is a low-energy β emitter that transfers
lower target doses. Its short emission range causes less
irradiation of tissues further away from the target tissue.
The availability of different radioisotopes potentially
allows tailoring radiopeptide therapy to the individual
patient.
The present study aimed to compare the efficacy and
toxicity of somatostatin-based radiopeptide therapy with
[90Y-DOTA]-TOC versus [177Lu-DOTA]-TOC in patients
with progressive neuroendocrine tumours.
Materials and methods
Patients
Patients were included in the case of histologically con-
firmed neuroendocrine tumours, metastasized disease, pro-
gression within 1 year before enrolment and detectable
tracer accumulation in the tumour in a somatostatin recep-
tor scan. Patients were excluded in the case of concurrent
anti-tumour treatment other than somatostatin treatment.
Furthermore, patients were excluded in the case of preg-
nancy, breastfeeding, incontinence, haematological toxicities
grade 3 or 4, or severe concomitant illness. Patients from
Europe, Asia, North America and South America were en-
rolled. The study was designed and carried out according to
good clinical practice, Swiss drug regulations and the
Declaration of Helsinki. It was approved by the Basel Ethics
Committee (Study number M120/97) and registered (Clinical
Trials identifier: NCT00978211). Written informed consent
was obtained from all patients.
Intervention
DOTA-TOC was synthesized and radiolabelled according to
Good Laboratory Practice (GLP) as previously described [12,
13]. [90Y-DOTA]-TOC was introduced at the University
Hospital Basel in October 1997, and [177Lu-DOTA]-TOC
became available after February 2001. The present study
Radioisotope:
90Y or 177Lu
Chelator:
DOTA
Targeting peptide: 
Tyr3-octreotide (TOC)
Receptor-binding sequence:
Tyr-d-Trp-Lys-Thr
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Fig. 1 Structure of the 90Y-
or 177Lu-labelled cyclic
radiopeptide DOTA-TOC (a).
Awhole-body scan 24 h after
injection of 7.4 GBq
[177Lu-DOTA]-TOC showing
tumour uptake in a patient with
extensive liver and bone
metastases from a small bowel
carcinoid (b)
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compares the outcome after [177Lu-DOTA]-TOC and [90Y-
DOTA]-TOC in patients with metastasized neuroendocrine
tumours from the time both tracers were available. There
were no strict criteria for allocating patients to both treat-
ment forms; however, [177Lu-DOTA]-TOC was predomi-
nantly used in patients with low tumour burden (≤3 le-
sions), small lesions (diameter <3 cm) or low kidney func-
tion with increased creatinine level (>90 μmol/L). Lysine-
and arginine-containing amino acid solutions were applied
before and after [177Lu-DOTA]-TOC and [90Y-DOTA]-TOC
injection to inhibit tubular reabsorption of the radiopeptide
[11, 14, 15].
Long-acting somatostatin analogues were withheld at least
6 weeks and short-acting somatostatin analogues were with-
held at least 3 days before radiopeptide therapy. All treatment
cycles were performed on an inpatient basis.
Based on the findings of our pilot study [14], thera-
peutic cycles were repeated at an interval of at least
6 weeks in the presence of at least one of the following
criteria: (1) stabilization or reduction in the summation of
the longest widths of all pre-therapeutically identified
lesions, (2) improvement in at least one of the five main
symptoms: flush, diarrhoea, pain, fatigue and weight loss
or (3) a detectable post-therapy marker decrease after
a pre-therapy marker increase. The following markers
were employed: hydroxyindoleacetic acid, angiotensin-
converting enzyme, adrenocorticotropic hormone, alphafeto-
protein, CA-125, CA-19.9, parathormone, calcitonin,
carcinoembryonic antigen, chromogranin A, dopamine, gas-
trin, glucagon, noradrenaline, neuron-specific enolase, pan-
creatic polypeptide, proinsulin, serotonin and vasoactive in-
testinal peptide.
Intratherapeutic imaging
The biodistribution of DOTA-TOC was evaluated with
planar whole-body scanning as previously described [11,
13, 16, 17] (Fig. 1b). The maximum tracer accumulation
in the tumour (tumour score ) and the kidneys (kidney
score ) was visually scored by three board-certified nu-
clear medicine physicians blinded to the patient’s base-
line and follow-up data using a four-point scale: no
tracer accumulation (score 0 ), tracer accumulation lower
than in the liver (score 1 ), tracer accumulation similar to that
in the liver (score 2 ) and tracer accumulation higher than that
in the liver (score 3 ).
Follow-up
All patients were monitored prior to and for 3 days after injec-
tion of DOTA-TOC, and adverse events were continually
logged. Following discharge, serum chemistry and haema-
tological parameters were assessed biweekly for 10 weeks or
until normalization of any pathological findings. The initial
post-therapy morphological imaging was planned 6–8 weeks
after treatment.
Additional DOTA-TOC cycles were suspended in the case
of progression, permanent toxicity or loss of the ability or the
willingness to travel to the treatment centre. At this time,
follow-up was aimed at gathering data on survival and adverse
events, including renal toxicity, until the patient’s death.
Follow-up information was gathered from the referring cen-
tres; family physicians and patients were contacted if further
follow-up information was required. All follow-up informa-
tion was centrally gathered and all individual cases were
reviewed and checked for completeness at the study centre.
All toxicities were categorized in accordance with the
Common Terminology Criteria for Adverse Events (CTCAE)
v. 3.0 of the National Cancer Institute. Renal function was
evaluated with the Modification of Diet in Renal Disease
(MDRD) formula [18]; renal adverse events were categorized
in accordance with the guidelines of the National Kidney
Foundation.
Statistical analysis
Primary endpoints were survival and severe renal toxicity.
Severe renal toxicity was defined as toxicity grade 4 or 5
(glomerular filtration rate <30 or <15 ml/min per 1.73 m2).
Survival was evaluated from time of enrolment to death.
Survival predictors were evaluated using multivariable
Cox regression with the subsequent pre-specified prognostic
variables: gender, age, histology, duration of disease, prior
surgery, prior chemotherapy, prior radiation, single lesion vs
multiple lesions, liver lesions vs no liver lesions, bone lesions
vs no bone lesions, tumour uptake score and treatment with
[177Lu-DOTA]-TOC vs treatment with [90Y-DOTA]-TOC.
Pre-specified subgroup analyses were performed to inves-
tigate survival effects in subgroups with low vs high tumour
accumulation, solitary vs multiple lesions, liver lesions vs no
liver lesions and bone lesions vs no bone lesions. Based on
previous results from an animal model [19], we hypothesized
that [177Lu-DOTA]-TOCwould be advantageous in terms of a
survival benefit in patients with limited tumour burden, e.g.
solitary metastases, which in our cohort are common in extra-
hepatic disease, and small metastases, which in planar scin-
tigraphy often show low tumour uptake. Furthermore, both
drugs might have different effects in patients with bone me-
tastases as free 177Lu and 90Y are incorporated into the bone.
We added each of these baseline variables in turn to our
statistical model together with the corresponding interaction
term with treatment group. In the case of any statistically
significant interactions, we simultaneously added the signifi-
cant interaction terms to the model in order to identify any
independent interactions. Effect estimates were reported using
hazard ratios (HR) with 95 % confidence intervals (CI).
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The haematotoxicity rates for [177Lu-DOTA]-TOC and
[90Y-DOTA]-TOC were compared employing logistic regres-
sion using the same set of co-variables as specified for the
survival analyses.
In order to correctly identify predictors of renal ad-
verse events the competing risk of death prior to renal
adverse events was included into all analyses. Cumulative
incidence functions were employed to identify the per-
centage of patients with renal adverse events or the
competing event of death [20] and a Fine and Gray regression
model for the subdistribution hazard [21] was established. The
subsequent pre-specified cofactors were used for these calcu-
lations: gender, age, glomerular filtration rate at time of enrol-
ment and allocation to [177Lu-DOTA]-TOC or [90Y-DOTA]-
TOC.
Response evaluation using RECIST was established
in 2000, 36 months after enrolment of the first patient
[22], and was not an a priori study outcome. In a supplemen-
tary analysis, all CT and MRI imaging results were
revised to include all patients, in whom RECIST was
applicable.
Further sensitivity analyses were performed to identify the
effect of the year of treatment and the effect of all pre-specified
co-variables on the 1-, 2- and 5-year survival, respectively. A
two-sided p value of <0.05 was considered to indicate statis-
tical significance.
Results
Patients
From February 2001 to February 2010, 1,744 patients were
screened for eligibility. Of these patients, 103 (5.9 %) were
not eligible and 590 patients (33.8 %) were eligible but not
stratified for either [177Lu-DOTA]-TOC or [90Y-DOTA]-
TOC (Fig. 2). The remaining 1,051 patients (60.3 %) were
enrolled either for [177Lu-DOTA]-TOC or for [90Y-DOTA]-
TOC. These patients were referred from more than 100
institutions in 27 countries (Switzerland: 291 patients;
Germany: 270; USA: 150; Israel: 95; Denmark: 78;
France: 74; Hungary: 51; Spain: 7; Luxembourg: 6;
Turkey: 4; Arabic Emirates, Brazil, Croatia, Italy, Japan,
Netherlands, Portugal, Ukraine: 2 patients each; Austria,
Belgium, Latvia, Mexico, Pakistan, Slovakia, Slovenia,
South Africa, UK: 1 patient each); their baseline data are
presented in Table 1.
Treatment
Overall, 141 patients underwent 259 cycles of [177Lu-DOTA]-
TOC (median number of cycles 2, range 1–5) with a mean
cumulative activity of 13.5±6.5 GBq. Re-treatment was
performed due to clinical improvement (36 patients,
25.5 %), post-therapeutic tumour marker decrease (23 pa-
tients, 16.3 %; median marker decrease 54.1 %, interquartile
range 43.3–75.1%) and/or stabilization or decrease in the sum
of diameters of the detected tumour lesions (34 patients,
24.1 %). RECIST could be applied in 16 of those 34 patients
(47.0 %), with partial response in 7 (5.0 %) and stable disease
in 9 patients (6.4 %).
A total of 910 patients underwent 1,804 cycles of [90Y-
DOTA]-TOC (median number of cycles 2, range 1–6) with a
mean cumulative activity of 13.1±4.7 GBq. Re-treatment was
performed due to clinical improvement (230 patients, 25.3%),
post-therapeutic tumour marker decrease (147 patients,
16.2 %; median marker decrease 56.8 %, interquartile range
40.7–73.1 %) and/or stabilization or decrease in the sum of
diameters of the detected tumour lesions (331 patients,
36.4 %). RECIST could be applied in 142 of those 331
patients (42.9 %), with partial response in 62 (6.8 %), stable
disease in 75 (8.2 %) and complete remission in 5 patients
(0.5 %). Their median progression-free interval was
12.7 months (range 2.1–21.2 months).
No significant differences in response rates were
found in the subgroups of patients with low vs high
tumour accumulation, solitary vs multiple lesions, liver
lesions vs no liver lesions and bone lesions vs no bone
lesions.
Survival
In the [177Lu-DOTA]-TOC group, 48 patients (34.0%) died and
93 (66.0 %) survived throughout a median follow-up of
9.0 months (1.0–80.1 months). In the [90Y-DOTA]-TOC group,
360 patients (39.6 %) had died and 545 patients (59.9 %) had
survived during a median follow-up of 11.0 months (1.0–
100.7 months); 5 patients (0.5 %) were not available for
follow-up.
The overall median survival of the [177Lu-DOTA]-TOC
group and the [90Y-DOTA]-TOC group was comparable
(45.5 vs 35.9 months, HR 0.91, 95 % CI 0.63–1.30, p =
0.49, Fig. 3a). The subgroup analyses revealed statistically
significant interactions suggesting longer survival with
[177Lu-DOTA]-TOC in patients with low tumour accumula-
tion (Fig. 3b), solitary lesions (Fig. 3c) and extra-hepatic
lesions (Fig. 3d) when compared with [90Y-DOTA]-TOC in
a multivariable regression (Fig. 4). No significant differences
in effects were found in the subgroup of patients with bone
lesions vs no bone lesions (Fig. 3e). When all three significant
interaction terms were simultaneously added to the statistical
model, only the low tumour uptake effect remained close to
statistical significance (p =0.09).
Sensitivity analyses found no significant differences in
survival after [177Lu-DOTA]-TOC and [90Y-DOTA]-TOC in
patients with carcinoids (n =402, p =0.39), pancreatic
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Fig. 2 Patient flow. “Loss of
transferability” refers to the loss
of the patient’s ability to travel to
the treatment centre to receive
radiopeptide therapy
Table 1 Baseline patient
characteristics
PNET pancreatic neuroendocrine
tumours, NET neuroendocrine
tumours, Rare NET comprise
medullary thyroid cancers,
neuroblastomas,
phaeochromocytomas,
paragangliomas, small cell lung
cancers and Merkel cell tumours
Characteristic [90Y-DOTA]-TOC (n =910) [177Lu-DOTA]-TOC (n =141)
Gender Female 400 (44.0 %) 59 (41.8 %)
Male 510 (56.0 %) 82 (58.2 %)
Age (years) Median 59.6 62.4
Range 11.2–91.1 14.8–83.4
Disease duration (years) Median 1.9 1.4
Range 0.1–37.8 0.1–30.8
Pretreatment Surgery 500 (54.9 %) 79 (56 %)
Chemotherapy 274 (30.1 %) 17 (12.1 %)
Radiation 97 (10.7 %) 46 (32.6 %)
Extent Single lesion 87 (9.6 %) 43 (30.5 %)
Liver metastases 748 (82.2 %) 71 (50.4 %)
Bone metastases 163 (17.9 %) 22 (15.6 %)
Creatinine (μmol/L) Median 70 95
Range 27–434 26–585
Tumour uptake Score 1 48 (5.3 %) 45 (39.1 %)
Score 2 51 (5.6 %) 22 (15.6 %)
Score 3 811 (89.1 %) 74 (52.5 %)
Kidney uptake Score 0 49 (5.4 %) 7 (5.0 %)
Score 1 114 (12.5 %) 9 (6.4 %)
Score 2 218 (24.0 %) 23 (16.3)
Score 3 524 (57.6 %) 102 (72.3 %)
Histology Carcinoid 402 (44.2 %) 61 (43.3 %)
PNET 277 (30.4 %) 26 (18.4 %)
Rare NET 68 (7.5 %) 24 (17.0 %)
Unknown primary 163 (17.9 %) 30 (21.3 %)
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neuroendocrine tumours (n =277, p =0.93), rare neuroendo-
crine tumours (n =68, p =0.90) and neuroendocrine tumours
of unknown origin (n =163, p =0.78). The HR for the main
co-variables did not vary over the observed interval. All
predictors of the 1-, 2- and 5-year survival are presented in
the Supplementary Table A.
Toxicities
In the [177Lu-DOTA]-TOC group, two cases (1.4 %) of tran-
sitory grade 3/4 haematotoxicity occurred (both cases with
thrombocytopenia). Myeloproliferative disorders did not oc-
cur after [177Lu-DOTA]-TOC. In 13 patients (9.2 %) severe
permanent renal toxicity occurred (8 cases of grade 4 and 5
cases of grade 5). At the time of enrolment, 42 of 141 patients
receiving [177Lu-DOTA]-TOC had a glomerular filtration rate
of >90 ml/min per 1.73 m2. In two (4.8 %) of these patients
severe permanent renal toxicity (no cases of grade 4 and two
cases of grade 5) occurred.
In the [90Y-DOTA]-TOC group, 92 cases (10.1 %, p =
0.001 compared to [177Lu-DOTA]-TOC group) of transitory
grade 3/4 haematotoxicity occurred (leucopenia 59 patients,
anaemia 10 patients, thrombocytopenia 57 patients). In 71
patients (7.8 %, p =0.39 compared to [177Lu-DOTA]-TOC
group) severe permanent renal toxicity occurred (53 cases of
grade 4 and 18 cases of grade 5). At the time of enrolment, 510
of 910 patients receiving [90Y-DOTA]-TOC had a glomerular
filtration rate of >90 ml/min per 1.73 m2. In 24 (4.7 %) of
these severe permanent renal toxicity (16 cases of grade 4 and
8 cases of grade 5) occurred.
At the time of enrolment, 20 patients had a glomerular
filtration rate below 30 ml/min per 1.73 m2; the other 1,031
patients were included in the competing risks analyses to
identify predictors of renal adverse events. These analyses
found no difference in the risk for renal adverse events after
[177Lu-DOTA]-TOC or [90Y-DOTA]-TOC. The main risk
factor for renal adverse events was a reduced glomerular
filtration rate at the time of enrolment (Table 2 and Fig. 3f).
Discussion
This study in 1,051 neuroendocrine tumour patients showed
no difference in overall survival between patients undergoing
[177Lu-DOTA]-TOC and patients undergoing [90Y-DOTA]-
TOC treatment. However, subgroup analyses found evidence
for differential effects of both drugs. Patients with low tumour
accumulation, solitary lesions and extra-hepatic lesions sur-
vived longer on [177Lu-DOTA]-TOC, while patients with
higher tumour accumulation, multiple lesions and liver lesions
may benefit from [90Y-DOTA]-TOC. Significantly fewer pa-
tients experienced haematotoxicity after [177Lu-DOTA]-TOC
therapy than after [90Y-DOTA]-TOC therapy.
The observed differences of therapeutic efficacy in several
patient subgroups may derive from the properties of both
radioisotopes. The high-energyβ emitter 90Y is able to induce
high target doses. With its maximum range of 12 mm, it can
deposit about 87 % of its energy in a 3-cm lesion; however, it
can only deposit 63 % in a 1-cm lesion [23]. Conversely, the
lower-energy β emitter 177Lu induces lower target doses.
Nevertheless, with its emission range of 2.1 mm, it can deposit
about 81 % of its energy in a 1-cm lesion [23]. The advantage
of using 90Y for larger lesions and 177Lu in smaller lesions had
formerly been suggested based on animal studies [19]. The
present data support the hypothesis and indicate beneficial
effects of [177Lu-DOTA]-TOC over [90Y-DOTA]-TOC in ear-
ly stages with solitary metastases.
The described subgroup effects meet the criteria for cred-
ible subgroup analyses [24]. Only a small number of a priori
defined hypotheses were tested. All hypotheses were derived
from a rationale developed in an animal model [19]. All
subgroup variables are characteristics measured at baseline.
The directions of the subgroup effects were defined a priori
and assessed within one study. Large and significant effect
sizes were found. As especially small solitary extra-hepatic
metastases show low tumour uptake in the planar whole-body
scan, a correlation of subgroup effects was found when simul-
taneously adding all significant interaction terms to the model.
Haematotoxicity is an acute toxicity that can be due to
irradiation from [90Y-DOTA]-TOC or [177Lu-DOTA]-TOC cir-
culating through the body or binding to somatostatin receptors
on bone marrow cells [25] or due to the small fraction of free
90Y and 177Lu that is administered during treatment cycles and
that integrates into the bone matrix [26]. The present study
found higher rates of haematotoxicity after [90Y-DOTA]-TOC
as compared to [177Lu-DOTA]-TOC. [177Lu-DOTA]-TOC
might be preferable in patients with a reduced bone marrow
function.
Until now, only inter-study comparisons of renal toxicity
after 90Y- and 177Lu-based radiopeptide therapy were avail-
able [11, 16, 17, 27]. There are several reasons why these
studies commonly found lower kidney toxicity rates than
reported in the present study. First, we allowed patients with
reduced kidney function very close to severe renal toxicity
who per se have a high likelihood of developing severe renal
toxicity to be included. Second, the long follow-up period in
Fig. 3 Survival and renal adverse events. Covariate-adjusted Kaplan-
Meier estimates of overall survival are shown for [177Lu-DOTA]-TOC
versus [90Y-DOTA]-TOC treatment (a ). b Cumulative incidence
functions displaying the proportion of patients with renal adverse events
for [177Lu-DOTA]-TOC and [90Y-DOTA]-TOC and the competing event
of death (dotted line). Furthermore, covariate-adjusted Kaplan-Meier
estimates of survival after [177Lu-DOTA]-TOC versus [90Y-DOTA]-
TOC treatment are shown for patients with low tumour uptake (tumour
score = 1, c), solitary metastases (d), extra-hepatic metastases (e) and
bone metastases (f)
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No. of patients Hazard ratio P value
[177Lu-DOTA]-TOC 141 48 3.79 years 0.91 vs. [90Y-DOTA]-TOC
[90Y-DOTA]-TOC 910 360 2.99 years
a Overall survival
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f s
ur
vi
va
l
Time since start of treatment (y)
No. at risk
141 32 9 2 0 0[177Lu-DOTA]-TOC
1051 328 134 42 7 0Total
910 296 125 40 7 0[90Y-DOTA]-TOC
1.0
0.8
0.6
0.4
0.2
0.0
0 2 4 6 8 10
[177Lu-DOTA]-TOC 43 8 4.66 years 0.30 vs.[90Y-DOTA]-TOC 0.02
[90Y-DOTA]-TOC 86 34 3.94 years
c Survival of patients with solitary metastases 
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l
No. at risk
43 13 3 0 0 0[177Lu-DOTA]-TOC
129 37 13 4 1 0Total
86 24 10 4 1 0[90Y-DOTA]-TOC
1.0
0.8
0.6
0.4
0.2
0.0
0 2 4 6 8 10
Time since start of treatment (y)
[177Lu-DOTA]-TOC 22 12 2.13 years 1.07vs. [90Y-DOTA]-TOC 0.87
[90Y-DOTA]-TOC 161 82 2.47 years
e Survival of patients with bone metastases 
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f S
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vi
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l
No. at risk
22 4 2 0 0 0[177Lu-DOTA]-TOC
183 41 15 2 0 0Total
161 37 13 2 0 0[90Y-DOTA]-TOC
1.0
0.8
0.6
0.4
0.2
0.0
0 2 4 6 8 10
Time since start of treatment (y)
[177Lu-DOTA]-TOC 45 10 4.83 years 0.15 vs.[90Y-DOTA]-TOC <0.001
[90Y-DOTA]-TOC 47 28 2.48 years 
b Survival of patients with low tumor uptake 
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ty
 o
f S
ur
vi
va
l
No. at risk
45 15 5 2 0 0[177Lu-DOTA]-TOC
92 26 9 5 1 0Total
47 11 4 3 1 0[90Y-DOTA]-TOC
1.0
0.8
0.6
0.4
0.2
0.0
0 2 4 6 8 10
Time since start of treatment (y)
[177Lu-DOTA]-TOC 59 16 4.43 years 0.42 vs.[90Y-DOTA]-TOC 0.012
[90Y-DOTA]-TOC 160 62 3.77 years
d Survival of patients with extra-hepatic metastases
Pr
ob
ab
ili
ty
 o
f S
ur
vi
va
l
No. at risk
59 19 8 2 0 0[177Lu-DOTA]-TOC
219 71 27 10 0 0Total
160 52 19 8 0 0[90Y-DOTA]-TOC
1.0
0.8
0.6
0.4
0.2
0.0
0 2 4 6 8 10
Time since start of treatment (y)
Pr
ob
ab
ili
ty
 o
f K
id
ne
y 
To
xi
ci
ty
f Overall incidence of kidney toxicities 
[177Lu-DOTA]-TOC 133 13 1.39 vs.[90Y-DOTA]-TOC 0.32
[90Y-DOTA]-TOC 898 71
1.0
0.8
0.6
0.4
0.2
0.0
0 2 4 6 8 10
Time since start of treatment (y)
No. at risk
133 30 7 2 0 0[177Lu-DOTA]-TOC
1031 326 133 42 7 0Total
898 296 126 40 7 0[90Y-DOTA]-TOC
0.49 
No. of deaths Median survival
No. of patients Hazard ratio P valueNo. of deaths Median survival
No. of patients Hazard ratio P valueNo. of deaths Median survival No. of patients Hazard ratio P valueNo. of deaths
No. of patients Hazard ratio P valueNo. of deaths Median survival
No. of patients Hazard ratio P valueNo. of deaths Median survival
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many patients implicates an additional natural decrease in
kidney function and a high possibility of nephrotoxic inter-
ventions after DOTA-TOC therapy. Third, our thorough
follow-up until the patients’ death was predisposed to detect
decreased renal function. However, the cause for differences
in renal toxicities found between each different study will
remain widely unapparent. These differences, however, high-
light the importance of increased comparative effectiveness
research in radiopeptide therapy. In the present comparative
study both treatment groups were followed up equally and the
duration of follow-up was adequate to identify kidney toxic-
ities that occur months after [177Lu-DOTA]-TOC and [90Y-
DOTA]-TOC therapy. As patients with pre-existing low base-
line renal function were enrolled, the baseline renal function in
both treatment groups, and especially in the [177Lu-DOTA]-
TOC group, was lower than in the reports of other groups.
When correcting for the baseline kidney function, however,
no significant difference was detected in the renal toxicity of
[90Y-DOTA]-TOC as compared to [177Lu-DOTA]-TOC.
Further comparative studies are warranted to assess potential
differences in renal toxicity after 90Y- and 177Lu-based
radiopeptide therapy.
Strengths of the present study include the recruitment of
1,051 patients, allowing for powerful analyses, while the
limited number of pre-specified co-variables in the regression
model and the limited number of pre-specified subgroup
analyses allowed the risk of overfitting and data-driven asso-
ciations to be minimized. The single-centre design provided
homogeneity of intervention among all patients. Advances in
supportive care during the enrolment period of 9 years might
have influenced the individual patient survival; however, no
significant influence of the enrolment date on any of the
described effects was found. Especially, the longer survival
of [177Lu-DOTA]-TOC over [90Y-DOTA]-TOC in the patient
subgroups with low tumour accumulation, solitary lesions and
extra-hepatic lesions was independent from the patients’ time
of recruitment. Nevertheless, allocation to the treatment arms
was done in a non-randomized fashion. All analyses were
Fig. 4 Subgroup analyses. HR for mortality from multivariable Cox regression models investigating [177Lu-DOTA]-TOC versus [90Y-DOTA]-TOC are
shown for pre-specified patient subgroups
Table 2 Survival analyses and competing risks analyses
Cofactor HR (95 % CI)a p value
Survival
Gender (male vs females) 0.94 (0.77–1.14) 0.53
Age (per 10 years) 1.18 (1.09–1.29) <0.001
Disease duration (per year) 0.99 (0.96–1.01) 0.38
Prior surgery (vs no surgery) 0.75 (0.60–0.94) 0.012
Prior chemotherapy (vs no chemotherapy) 1.87 (1.52–2.30) <0.001
Prior radiation (vs no radiation) 0.94 (0.68–1.29) 0.68
Single lesions (vs multiple metastases) 0.78 (0.50–1.23) 0.29
Liver lesions (vs no liver metastases) 1.31 (0.93–1.83) 0.12
Bone lesions (vs no bone metastases) 1.87 (1.45–2.40) <0.001
Tumour uptake score 2 (vs uptake score 1) 0.77 (0.43–1.39) 0.38
Tumour uptake score 3 (vs uptake score 1) 0.45 (0.26–0.78) 0.004
[177Lu-DOTA]-TOC (vs [90Y-DOTA]-
TOC)
0.91 (0.63–1.30) 0.49
Severe kidney toxicity
Gender (male vs female) 0.80 (0.51–1.23) 0.30
Age (per 10 years) 1.21 (0.98–1.49) 0.07
Baseline glomerular filtration rate
(per 10 ml/min per 1.73 m2)
0.57 (0.48–0.67) <0.001
[177Lu-DOTA]-TOC (vs [90Y-DOTA]-
TOC)
1.39 (0.72–2.68) 0.32
a Estimates for all co-variables have been adjusted for histology as a
categorical co-variable and for all further co-variables above
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adjusted for the relevant known prognostic co-variables, but
unidentified factors might have been unbalanced between the
treatment groups. Finally, although the present analysis meets
current criteria for credible subgroup effects, our finding
should be interpreted cautiously and confirmatory evidence
is warranted.
In conclusion, this study compares survival and long-term
toxicities of therapeutic regimens using the two most widely
employed radioisotopes for radiopeptide therapy. Its results
indicate longer survival for [177Lu-DOTA]-TOC over [90Y-
DOTA]-TOC in patients with low tumour accumulation, sol-
itary lesions and extra-hepatic lesions, while patients with
higher tumour accumulation, multiple lesions and liver lesions
may benefit from [90Y-DOTA]-TOC. Furthermore, the present
results indicate lower haematotoxicity of [177Lu-DOTA]-TOC
treatment in comparison to [90Y-DOTA]-TOC treatment.
These results may represent a step towards individual tailoring
of somatostatin-based radiopeptide therapy.
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